Loading
  • News
  • Investors
  • Careers
  • Contact
  • X
  • About Us
    • Our Mission & Vision
    • The Zevra Story
    • Leadership
    • Board of Directors
  • Our Approach
    • What We Do
    • Partnering
  • Patients & Providers
    • Niemann-Pick Disease Type C
    • Sleep Disorders
    • Expanded Access Policy
    • Clinical Trials
  • Science & Pipeline
    • Pipeline
    • Clinical Trials
    • Products
    • Publications & Presentations
  • Investors
    • Investor Relations
    • Events & Presentations
    • Stock Quote & Chart
    • Press Releases
    • Corporate Governance
    • SEC Filings
    • Contact
    • Email Alerts
  • Careers
    • Culture
    • Job Openings
  • Contact
    • info@zevra.com
    • 888.958.1253
    • Facebook
    • Twitter
    • LinkedIn
  • Home
  • Menu Menu

Science & Pipeline

Our expertise, elegant solutions, and transparent data narratives have produced a late-stage rare disease clinical pipeline and two partnered commercial products.

Product candidate
Indication
Phase 1 Phase 2 Phase 3 NDA Submission
Milestones

Niemann-Pick Disease Type C (NPC) Program

Arimoclomol

Orally-delivered, first-in-class investigational product candidate for NPC.

Niemann-Pick Disease Type C (NPC)

NDA SUBMISSION

Arimoclomol NDA resubmission to FDA in Q4 2023

Granted orphan drug designation, fast track designation, and rare pediatric disease designation for NPC by the European Medicines Agency (EMA) and FDA as a breakthrough therapy in NPC.

There are no approved treatments for NPC in the U.S. and there are an estimated 1,800 people with NPC in the U.S. and Europe.

Learn More

Rare Sleep Disorders Program

KP1077

Lead prodrug candidate for idiopathic IH and narcolepsy type I & II

Idiopathic Hypersomnia (IH)

Narcolepsy

Phase 2

Narcolepsy

Phase 1

KP1077 IH - Phase 2 trial in IH initiated Dec. 2022; Topline data from the completed trial are expected in the first half of 2024; potential Zevra commercial candidate

Phase 1 clinical trial in healthy volunteers initiated during Q2 2023 and currently enrolling

About KP1077

Serdexmethylphenidate (SDX) is Zevra’s proprietary prodrug of d-methylphenidate (d-MPH) and the sole active pharmaceutical ingredient (API) in KP1077, Zevra’s lead product candidates being developed for the treatment of idiopathic hypersomnia (IH) and narcolepsy, respectively. IH is a rare neurological sleep disorder that can exhibit symptoms similar to narcolepsy. Narcolepsy is a chronic neurological disorder that affects the brain's ability to control sleep-wake cycles. Zevra plans to conduct the clinical development of both product candidates under separate INDs.

KP1077 being investigated for IH has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of IH and may be eligible for expedited approval pathways. The U.S. Drug Enforcement Agency (DEA) has classified SDX as a Schedule IV controlled substance based on evidence suggesting SDX has a lower potential for abuse when compared to d-MPH, a Schedule II controlled substance.

KP1077 in Idiopathic Hypersomnia

Zevra is currently conducting a multicenter, dose-optimizing, double-blind, placebo-controlled, randomized-withdrawal Phase 2 clinical trial to evaluate the safety and efficacy of KP1077 as a treatment for IH. In addition to assessing the safety of SDX in this study, KP1077 is being investigated for its potential to address excessive daytime sleepiness, sleep inertia and cognitive dysfunctions such as difficulty to focus and memory lapses (also referred to as “brain fog”) associated with IH. The results of this trial will help inform the design of a potential pivotal Phase 3 study of KP1077 in patients with IH and a potential Phase 3 trial of KP1077 in patients with narcolepsy.

KP1077 in Narcolepsy

An Investigational New Drug (IND) application has been submitted for KP1077 in narcolepsy and the U.S. Food and Drug Administration (FDA) has notified Zevra that we may initiate a Phase 1 clinical trial of KP1077N. Zevra plans to initiate the first of several Phase 1 clinical trials of KP1077N as early as in the second quarter of 2023. This study is expected to provide additional information for optimizing the dosing regimen of KP1077 for the treatment of narcolepsy. One of the objectives will be to assess the pharmacokinetics of SDX when dosed in the morning versus at night. The Phase 1 studies are expected to potentially support New Drug Applications (NDAs) for both the IH and narcolepsy submissions.

Learn More
A photo of documents laid out on a desk with a stethoscope and pair of glasses nearby.

Clinical Trials

Phase 2/3 Trial of Arimoclomol in Niemann-Pick Type C

Arimoclomol has been studied in 500+ people across 10 phase 1, four phase 2 and three phase 2/3 clinical trials, with no significant issues with safety identified. Its capsule formulation is designed to be swallowed whole, but administration is flexible, allowing the drug substance to be mixed with soft foods and liquids or delivered through a gastric feeding tube, if needed. Thus far, our data have shown promising results.

A sub-study of the completed CT-ORZY-NPC-002 trial (NCT02612129) is ongoing, investigating the safety of arimoclomol in children below the age of two with NPC. See clinicaltrials.gov for further information. Note that the trial is listed as “active, not recruiting” since the main trial has been completed.

However, the sub-study is still recruiting.

View More

Ongoing Phase 2 Clinical Study (KP1077.D01) in Adults with Idiopathic Hypersomnia (IH)

NOW ENROLLING adults (18 years and older) with IH

Study KP1077.D01 is being conducted by Zevra to evaluate the safety and efficacy of KP1077 capsules in patients with IH.

KP1077 capsules contain serdexmethylphenidate (SDX), a prodrug of dexmethylphenidate. It is an investigational medication for treating excessive daytime sleepiness (EDS) and other symptoms of IH, including sleep inertia (difficulty of waking up in the morning), and brain fog (lack of focus and mental clarity; forgetfulness and confusion). SDX has a unique, slow release profile that could potentially provide stable control of sleepiness throughout the day, with low abuse potential.

The clinical study consists of a screening period (up to 5 weeks), a 5-week open-label dose optimization period during which the optimal SDX dose will be determined, followed by a 2-week double-blind, randomized withdrawal period.

For more information or to find a participating clinical site, visit here or www.kp1077d01.com.

View More

Topline data from Phase 1 Clinical Trial of KP1077 in Idiopathic Hypersomnia

In a phase 1 clinical trial, KP1077 was found to be well-tolerated.

KP1077’s impact on the heart was compared to immediate-release and long-lasting formulations of Ritalin®, a commonly prescribed stimulant for people with IH. It was found that KP1077 could be safely administered at higher doses than Ritalin. This exposure is expected to result in a pharmacokinetic profile that yields greater benefits for people with IH.

We have initiated a phase 2 clinical trial in patients with IH to further understand KP1077’s efficacy and safety, as well as to assess the symptoms and severity of “brain fog.” We expect to enroll approximately 48 adults with IH in more than 30 centers in the United States.

Part 1 of the trial will consist of a five-week open-label period during which patients will be matched to one of four doses of KP1077. Part 2 of the trial will entail a two-week period, during which two-thirds of participants will continue to receive their optimized dose while the remaining one-third will receive placebo.

For more information, see here.

View More

Commercial Product

Marketed Product
Indication
Commercial Partner
Milestones

ADHD Commercial Product

AZSTARYS®

serdexmethylphenidate and dexmethylphenidate

Attention Deficit Hyperactivity Disorder (ADHD) in patients age six and older

Corium Inc.

Potential to reach one or more milestones during 2023 and continued royalty revenue

Approved by the FDA in 2021, AZSTARYS is a prodrug for the treatment of ADHD in patients age six years or older.

For more information visit azstarys.com.

Publications and Presentations

Publications

Frontiers in Psychiatry

- 06/23/2023

Serdexmethylphenidate/dexmethylphenidate effects on sleep in children with attention-deficit/hyperactivity disorder

Read More

Journal of Inherited Metabolic Disease

- 08/21/2021

Efficacy and safety of arimoclomol in Niemann-Pick disease type C: Results from a double-blind, randomised, placebo-controlled, multinational phase 2/3 trial of a novel treatment

Read More

Patterson et al

- 02/12/2021

Validation of the 5-domain Niemann-Pick type C Clinical Severity Scale

Read More

Mengel et al

- 11/23/2020

Clinical disease progression and biomarkers in Niemann–Pick disease type C: a prospective cohort study

Read More

Drug Development & Delivery

- 03/01/2019

Prodrugs for ADHD Treatments: Opportunities & Potential to Fill Unmet Medical Needs

Read More

Pain Medicine

- 10/28/2017

Pharmacokinetics and Abuse Potential of Benzhydrocodone, a Novel Prodrug of Hydrocodone, After Intranasal Administration in Recreational Drug Users

Read More

Pain Medicine

- 08/25/2017

Relative Bioavailability, Intranasal Abuse Potential, and Safety of Benzhydrocodone/Acetaminophen Compared with Hydrocodone Bitartrate/Acetaminophen in Recreational Drug Abusers

Read More

Pharmacoepidemiology & Drug Safety

- 08/03/2017

Patterns of abuse and routes of administration for immediate-release hydrocodone combination products

Read More

Poster Presentations

52nd Child Neurology Society Annual Meeting

- 10/06/2023

Evaluation of the Long-Term Effect of Arimoclomol in NPC – 48 Months Data from CT-ORZY-NPC-002

Read More

52nd Child Neurology Society Annual Meeting

- 10/05/2023

Real World Data Collection in Niemann-Pick Disease Type C – Data from Expanded Access Program with Arimoclomol

Read More

Psych Congress 2023

- 09/09/23

Cardiovascular (CV) Safety and Pharmacokinetics (PK) of Serdexmethylphenidate (SDX), a Prodrug of d-Methylphenidate (d-MPH) Compared to Ritalin and Ritalin LA in a Single-Dose Crossover Study in Healthy Volunteers

Read More

Beyond Sleepy 2023 Conference

- 06/04/23

A Clinical Study with KP1077 in Adults with Idiopathic Hypersomnia

Read More

The 19th Annual WORLDSymposiumTM

- February 22 – 26, 2023

Association Between NPC Severity Score Domains and Corresponding Items of the Performance-based Scale for the Assessment and Rating of Ataxia (SARA)

Read More

The 19th Annual WORLDSymposiumTM

- February 22 – 26, 2023

Evaluation of the Long-Term Effect of Arimoclomol in NPC

Read More

Academy of Managed Care Pharmacy (AMCP)

- March 29 – April 1, 2022

Serdexmethylphenidate/d-Methylphenidate Capsules for Children With ADHD: Effects on SKAMP-C Evaluated Over 13 Hours in a Randomized, Double-blind, Placebo-controlled Laboratory Classroom Study

Read More

The American Professional Society of ADHD and Related Disorders (APSARD) 2022 Annual Conference

- January 14-16, 2022

Mass Balance and Metabolic Pathway Following Oral Administration of [14C]-Serdexmethylphenidate, a Novel Prodrug of d-Methylphenidate

Read More Listen

The American Professional Society of ADHD and Related Disorders (APSARD) 2022 Annual Conference

- January 14-16, 2022

Dose Proportionality and Effects of Food on the Pharmacokinetics of Single-Entity Serdexmethylphenidate

Read More Listen

Children and Adults with Attention-Deficit/Hyperactiviity Disorder

- November 4–6, 2021

Serdexmethylphenidate/d-Methylphenidate Capsules for Children With ADHD: Effects on SKAMP-C Evaluated Over 13 Hours in a Randomized, Double-blind, Placebo-controlled Laboratory Classroom Study

Read More

Psych Congress

- October 29–November 1, 2021

Steady-State Pharmacokinetics and Relative Bioavailability of Serdexmethylphenidate/d-Methylphenidate, a Treatment for Attention Deficit Hyperactivity Disorder Containing a Novel Prodrug of d-Methylphenidate

Read More

American Academy of Child & Adolescent Psychiatry

- October 18-30 2021

Single-dose Pharmacokinetics of Serdexmethylphenidate/d-Methylphenidate Capsules in Children and Adolescents With ADHD and Healthy Adults: An Evaluation of Age and Body Weight

Read More

American Psychiatric Nurses Association

- October 13-16, 2021

Serdexmethylphenidate/d-Methylphenidate Capsules for Children With ADHD: Effects on SKAMP-C and WREMB-R as Evaluated in a Randomized, Double-blind, Placebo-controlled Laboratory Classroom Study

Read More

American Academy of Child and Adolescent Psychiatry

- October 12-24, 2020

Patterns of Abuse of Prescription Stimulant Products from the National Addictions Vigilance Intervention Program (NAVIPPRO): 2010-2018

Read More

American Academy of Child and Adolescent Psychiatry

- October 14-19, 2019

Effect of Food and Alternative Dosing Methods on the Pharmacokinetics of KP415, an Investigational ADHD Product Containing the Prodrug, Serdexmethylphenidate (SDX)

Read More

The American Professional Society of ADHD and Related Disorders

- January 18-20, 2019

Single-dose Pharmacokinetics of KP415, an Investigational Product Containing the Prodrug Serdexmethylphenidate (SDX), in Children and Adolescents with ADHD

Read More

The American Professional Society of ADHD and Related Disorders

- January 18-20, 2019

Dose-Proportionality and Steady-State Pharmacokinetics of KP415, an Investigational ADHD Product Containing Serdexmethylphenidate (SDX), a Novel Prodrug of d-Methylphenidate

Read More

The American Professional Society of ADHD and Related Disorders

- January 18-20, 2019

Human Abuse Potential of Oral Serdexmethylphenidate (SDX), a Novel Prodrug of d-Methylphenidate, Compared to Focalin® XR and Phentermine in Recreational Stimulant Abusers

Read More

The American Professional Society of ADHD and Related Disorders

- January 18-20, 2019

Human Abuse Potential of Intranasal Serdexmethylphenidate (SDX), a Novel Prodrug of d-Methylphenidate, in Recreational Stimulant Abusers

Read More

American College of Neuropsychopharmacology

- December 9-13, 2018

Assessment of the Intravenous Abuse Potential Of Serdexmethylphenidate (SDX), a Novel, Investigational Prodrug of D-Methylphenidate: Evidence from Nonclinical and Clinical Studies

Read More

American Academy of Child & Adolescent Psychiatry

- October 22-27, 2018

Human Abuse Potential of Intravenous Serdexmethylphenidate (SDX), a Novel Prodrug of d-Methylphenidate, in Recreational Stimulant Abusers

Read More

American Academy of Child & Adolescent Psychiatry

- October 22-27, 2018

Dose-finding Study of Abuse-Related Effects of Intranasal d-Methylphenidate in Recreational Stimulant Abusers

Read More

American Professional Society for ADHD and Related Disorders

- January 12-14, 2018

Single- and Multiple-dose Pharmacokinetics of KP415, a Novel d-Methylphenidate Product Containing a Prodrug of d-Methylphenidate, in Healthy Volunteers

Read More

2017 International Conference on Opioids (ICOO)

- June 11-3, 2016

Pharmacokinetics and Abuse Potential of KP511, a Novel Prodrug of Hydromorphone, after Intranasal Administration in Recreation Drug Users

Read More

American Academy of Pain Medicine (AAPM) Annual Meeting

- March 15-19, 2017

Oral pharmacokinetics of KP511, a prodrug of hydromorphone, relative to hydromorphone in human volunteers

Read More

American Academy of Pain Medicine (AAPM) Annual Meeting

- March 15-19, 2017

Pharmacokinetics and Abuse Potential of Benzhydrocodone, A Novel Prodrug of Hydrocodone, After Intranasal Administration in Recreational Drug Users

Read More

2016 International Conference on Opioids (ICOO)

- June 5-7, 2016

Pharmacokinetics and Abuse Potential of Benzhydrocodone, a Novel Prodrug of Hydrocodone, After Intranasal Administration in Recreational Drug Users

Read More

2016 International Conference on Opioids (ICOO)

- June 5-7, 2016

Relative Bioavailability, Intranasal Abuse Potential, and Safety of Benzhydrocodone/Acetaminophen, a Novel Immediate-Release Hydrocodone Prodrug Combination, Compared With Hydrocodone Bitartrate/Acetaminophen in Recreational Drug Abusers

Read More

Filter & Sort

Date:

  • View All
  • 2017-Older
  • 2019-2018
  • 2021-2020
  • 2023-2022

Disease:

  • View All
  • ADHD
  • NPC
  • Other
  • Sleep Disorders

Drug:

  • View All
  • Drug 1
  • Drug 2
  • Drug 3
  • Drug 4
Reset Filters
  • X
  • About Us
    • Our Mission & Vision
    • The Zevra Story
    • Leadership
    • Board of Directors
  • Our Approach
    • What We Do
    • Partnering
  • Patients & Providers
    • Niemann-Pick Disease Type C
    • Sleep Disorders
    • Expanded Access Policy
    • Clinical Trials
  • Science & Pipeline
    • Pipeline
    • Clinical Trials
    • Products
    • Publications & Presentations
  • Investors
    • Investor Relations
    • Events & Presentations
    • Stock Quote & Chart
    • Press Releases
    • Corporate Governance
    • SEC Filings
    • Contact
    • Email Alerts
  • Careers
    • Culture
    • Job Openings
  • Contact
    • info@zevra.com
    • 888.958.1253
    • Facebook
    • Twitter
    • LinkedIn
  • Home

© 2023 Zevra Therapeutics. All rights reserved. | Privacy Policy | Terms of Use

Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settingsHide notification onlySettings

Cookie and Privacy Settings



How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.

We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.

Google Analytics Cookies

These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.

If you do not want that we track your visit to our site you can disable tracking in your browser here:

Other external services

We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Google reCaptcha Settings:

Vimeo and Youtube video embeds:

Other cookies

The following cookies are also needed - You can choose if you want to allow them:

Privacy Policy

You can read about our cookies and privacy settings in detail on our Privacy Policy Page.

Accept settingsHide notification only